Roche Holding AG (RHHBY) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

I'd like to inform you that all participants are in listen-only mode during the call. After the presentation, there will be a question and answer session. You're invited to send in questions for this throughout the entire session using the Q&A functionality of Zoom. In addition to that, you may also raise your virtual hand to address your questions verbally. For participants joining via phone, to raise your hand, you'll star 9 on your phone's dial pad. When you then get selected to ask your questions, please follow the instructions from the phone and press star six to unmute yourself. One last remark, if you would like to follow the presented slides on your end as well, please feel free to go to www.woosh.com slash investors to download the presentation. At this time, it's my pleasure to introduce you to Thomas Schinecker, CEO of Woosh Group. Mr. Schinecker, the stage is yours. Thank you very much and good morning and good afternoon everyone. I'm very much excited to share our half year 2026 results with you. We again had a strong performance and we truly made significant portfolio progress in the second quarter. Now, let me take you through this slide. I think the headline says everything. Co-operating profit growth at plus 10% ahead of sales growth at plus 6%. Again, increasing our margin, similar to what we have done over the last couple of years. Performance driven really by both divisions, both pharma and diagnostics. Diagnostics without the China impact is growing 6%. And let me just also reframe the impact of the flu season. The flu season had about a 1% or more than 200 million impact on the group results. So without that also, we will be growing at 7%. I already mentioned the strong bottom line performance with cooperating profit plus 10%, cooperating margin...